(Translation from Japanese Press Release)

Transfer of sales & distribution business of dialysis products from Fresenius
Medical Care Japan and hand over of Nikkiso’s Korean dialysis business toFresenius Medical Care
23rd July 2010
Nikkiso Co.,Ltd.
Nikkiso and Fresenius Medical Care (“FMC”) have agreed that Fresenius Medical Care
Japan (“FMCJ”) appoints and transfers to Nikkiso its dialysis products sales &distribution business in Japan and that Nikkiso hands over to FMC the entire
shareholding of Nikkiso Medical Korea, its 100% ownership dialysis related sales
subsidiary in Korea to FMC Korea.
1. Outline of sale and distribution transfer
Nikkiso’ main business is consisted of Industrial Division and Medical Division. In
the field of Medical Division, Nikkiso is the first company to introduce hemodialysis
machines to Japan. Presently, Nikkiso maintains the largest share of dialysis
machines in Japan and provides various products as a comprehensive dialysis
manufacturer, including PEPA dialyzers, which was developed by Nikkiso,
bloodlines, and dialysis concentrates.
FMC, having its headquarters in Germany, is the world largest dialysis related
business group and FMCJ is its subsidiary in Japan.
Based on the agreement, FMCJ appoints and transfers its entire sales business ofdialyzers in Japan to Nikkiso. Nikkiso will distribute FMC’s dialyzers in theJapanese market in addition to its own brand of PEPA dialyzers. By expanding its
product line-up with the Fresenius’ polysulfone dialyzers and based on highconfidence from its customers and the extensive sales network in Japan, Nikkiso isaiming to strengthen its dialysis consumables business. Nikkiso will also take overthe maintenance services for the existing dialysis machines of FMCJ.
FMCJ will also appoints and transfers its peritoneal dialysis (“PD”) related sales
and distribution business to Nikkiso and Nikkiso aims at further developing its
home dialysis business along with the home hemodialysis business which it has
been successfully promoting.
In the meantime, the existing customers of FMCJ (including FUSO PharmaceuticalIndustries, Ltd) will be succeeded by Nikkiso and both companies will do their best
to maintain its good relationship.
From now on, FMCJ will focus on the manufacturing, developing, and importing ofdialysis products in Japan.
1

By this new business scheme, Nikkiso and FMCJ strive to contribute to thecomprehensive dialysis treatment covering both hemodialysis and peritonealdialysis.

2. Transfer of Nikkiso’s dialysis business in Korea
Nikkiso hands over Nikkiso Medical Korea, its dialysis business subsidiary inKorea to FMC Korea and ceases its dialysis related business in Korea.
3. Schedule
Transfer Date : Aug. 2010 or later (expected)
4. Outlook
Nikkiso anticipates net sales increase through its own sales network as well as
existing track record of FMCJ’s dialyzer sales. As for FY ending Mar. 2011, the effectto its financial result is forecasted to be minor. However, by expediting the upgradeof sales force including PD products, Nikkiso will materialize further sales increase.

<For reference, the overview of Fresenius Medical Care>
FMC, with its headquarters in Germany, is the world largest dialysis-related
business group, developing its business at a global level with over 115 countries in
the world, manufacturing and marketing hemodialysis machines, dialyzers,
bloodlines, dialysis concentrates, and peritoneal dialysis-related products andrunning dialysis clinics. In 2009, its revenue was USD 11,247 million (about JPY 1trillion)
FMCJ is FMC’s 100% subsidiary in Japan, established in October 1993.

2